Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Trilogy International Partners	Futura Medical	Allergy Therapeutics	Avivagen	N4 Pharma
Symbol	TSE:TRL	LON:FUM	LON:AGY	CVE:VIV	LON:N4P
Price Information
Current Price	C$1.90	GBX 39.20	GBX 27	C$0.39	GBX 8.26
50-Day Moving Average	C$1.93	GBX 44.06	GBX 24.62	C$0.41	GBX 8.60
52-Week Low	C$0.85	GBX 12.11	GBX 12.40	C$0.33	GBX 4.43
52-Week High	C$2.11	GBX 84	GBX 27.70	C$0.78	GBX 16
MarketRank™
Overall Score	1.6	1.2	0.8	0.5	0.5
Analysis Score	3.5	3.5	0.0	0.0	0.0
Community Score	3.0	2.4	3.2	2.5	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.0	0.0	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	N/A	N/A	N/A
Consensus Price Target	C$3.33	GBX 102	N/A	N/A	N/A
% Upside from Price Target	75.44% upside	160.20% upside	N/A	N/A	N/A
Trade Information
Market Cap	C$113.85 million	£112.53 million	£173.28 million	C$22.21 million	£14.95 million
Beta	N/A	N/A	N/A	N/A	N/A
Average Volume	30,867	1,777,560	319,423	110,091	2,039,439
Sales & Book Value
Annual Revenue	C$626.85 million	£31,778.00	£81.76 million	C$1.32 million	£23,524.00
Price / Sales	0.18	3,541.19	2.12	16.80	635.44
Cashflow	C$1.17 per share	GBX 0.38 per share	GBX 7.50 per share	C$0.07 per share	GBX 1.97 per share
Price / Cash	1.63	103.13	3.60	5.33	4.20
Book Value	C($1.60) per share	GBX 0.30 per share	GBX 9.20 per share	C($0.02) per share	GBX 2 per share
Price / Book	-1.19	1.31	0.03	-18.57	0.04
Profitability
Net Income	N/A	N/A	N/A	N/A	N/A
EPS	C($0.99)	GBX (1)	GBX 1	C($0.12)	GBX (1)
Trailing P/E Ratio	N/A	N/A	27.00	N/A	N/A
Forward P/E Ratio	∞	∞	∞	∞	∞
P/E Growth	39.78	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	N/A	N/A	N/A	N/A	N/A
Return on Assets (ROA)	N/A	N/A	N/A	N/A	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	20.42%	2,402.32%	1.62%
Current Ratio	1.16%	2.06%	4.23%	0.97%	22.63%
Quick Ratio	0.77%	2.03%	3.61%	0.77%	22.54%
Ownership Information
Institutional Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Insider Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Miscellaneous
Employees	1,663	13	600	14	5
Shares Outstanding	59.92 million	287.07 million	641.77 million	56.96 million	181.08 million
Next Earnings Date	8/10/2021 (Estimated)	9/14/2021 (Estimated)	N/A	9/1/2021 (Estimated)	N/A
Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	N4 Pharma (LON:N4P) Trading 2.7% Higher americanbankingnews.com - July 10 at 12:09 AM
	Rurelec hit by delays in setting tariffs for Argentinian turbine proactiveinvestors.co.uk - May 20 at 5:08 PM
	Fevertree shares bubble up after rise in off-trade sales during lockdown proactiveinvestors.co.uk - May 20 at 12:08 PM
	Kanabo in demand after manufacturing agreement for cannabis products proactiveinvestors.co.uk - May 20 at 7:06 AM
	N4 Pharma in demand after it unveils agreements with two major companies proactiveinvestors.co.uk - May 20 at 7:06 AM
	We're Not Very Worried About N4 Pharma's (LON:N4P) Cash Burn Rate finance.yahoo.com - March 2 at 7:33 AM
	N4 Pharma losses widen as it works on commercialising Nuvec sharecast.com - February 24 at 12:37 PM
	N4 Pharma books annual loss on higher R&D spend shareprices.com - February 24 at 7:37 AM
	N4 Pharma PLC - Final Results proactiveinvestors.co.uk - February 24 at 7:37 AM
	N4 Pharma PLC - Notification of Intention to Grant Patent proactiveinvestors.co.uk - February 11 at 8:31 AM
	N4 Pharma PLC cnbc.com - January 23 at 11:11 PM
	N4 Pharma PLC - Placing to raise £2 million proactiveinvestors.co.uk - December 11 at 6:22 PM
	N4 Pharma executes 'oversubscribed' capital raise stockmarketwire.com - December 9 at 5:42 PM
	N4 Pharma PLC - Second Price Monitoring Extn proactiveinvestors.co.uk - November 27 at 12:50 AM
	N4 Pharma PLC - Price Monitoring Extension proactiveinvestors.co.uk - November 27 at 12:50 AM
	How Much Did N4 Pharma's (LON:N4P) CEO Pocket Last Year? finance.yahoo.com - November 23 at 12:00 PM
	UBA Gross Earnings Hits N454.4Bn, Delivers NN90.4Bn PBT in Q3 msn.com - November 22 at 8:57 PM
	IB Plc posts N4.6bn sales increase in Q3 msn.com - November 22 at 8:57 PM
	N4 Pharma PLC - SP Angel Research Note proactiveinvestors.co.uk - November 19 at 1:38 PM
	Remote Monitored Sys - Second Price Monitoring Extn proactiveinvestors.co.uk - November 13 at 11:19 PM
	N4 Pharma Plc Regulatory News lse.co.uk - November 5 at 11:07 PM
	N4 Pharma realigns product towards COVID-19 stockmarketwire.com - September 17 at 8:22 AM
	Bolsa de Londres: Índice FTSE 100 abre estável nesta segunda-feira, 14 de setembro de 2020 br.advfn.com - September 15 at 12:28 AM
	N4 Pharma get nul points from coronavirus antibody trial proactiveinvestors.co.uk - September 14 at 9:26 AM
	N4 Pharma to conduct new Covid-19 research after negative study result stockmarketwire.com - September 14 at 4:25 AM

Date	Company	Brokerage	Action
7/14/2021	Trilogy International Partners	Royal Bank of Canada	Boost Price Target
6/3/2021	Futura Medical	Liberum Capital	Boost Price Target
5/13/2021	Trilogy International Partners	Scotiabank	Boost Price Target
5/13/2021	Trilogy International Partners	TD Securities	Boost Price Target
4/14/2021	Futura Medical	Liberum Capital	Reiterated Rating
3/30/2021	Trilogy International Partners	TD Securities	Boost Price Target
3/30/2021	Trilogy International Partners	Royal Bank of Canada	Reiterated Rating
12/10/2020	Trilogy International Partners	TD Securities	Boost Price Target
11/12/2020	Trilogy International Partners	TD Securities	Boost Price Target
7/16/2020	Trilogy International Partners	TD Securities	Boost Price Target
7/15/2020	Allergy Therapeutics	FinnCap	Reiterated Rating
7/14/2020	Futura Medical	Liberum Capital	Reiterated Rating
7/9/2020	Allergy Therapeutics	FinnCap	Reiterated Rating
6/24/2020	Futura Medical	Liberum Capital	Reiterated Rating
6/24/2020	Allergy Therapeutics	FinnCap	Reiterated Rating
5/20/2020	Trilogy International Partners	TD Securities	Upgrade
5/18/2020	Futura Medical	Liberum Capital	Reiterated Rating
4/20/2020	Futura Medical	Liberum Capital	Reiterated Rating
4/1/2020	Futura Medical	Liberum Capital	Reiterated Rating
3/26/2020	Trilogy International Partners	Scotiabank	Lower Price Target
3/26/2020	Trilogy International Partners	Royal Bank of Canada	Lower Price Target
3/23/2020	Trilogy International Partners	TD Securities	Downgrade
3/18/2020	Futura Medical	Liberum Capital	Reiterated Rating
3/4/2020	Allergy Therapeutics	FinnCap	Reiterated Rating
2/13/2020	Futura Medical	Liberum Capital	Reiterated Rating
2/3/2020	Allergy Therapeutics	FinnCap	Reiterated Rating
1/16/2020	Allergy Therapeutics	FinnCap	Reiterated Rating
12/23/2019	Futura Medical	Liberum Capital	Reiterated Rating
12/10/2019	Futura Medical	Liberum Capital	Reiterated Rating
12/4/2019	Trilogy International Partners	TD Securities	Lower Price Target
11/28/2019	Futura Medical	Liberum Capital	Reiterated Rating
11/28/2019	Allergy Therapeutics	FinnCap	Reiterated Rating
11/15/2019	Futura Medical	Liberum Capital	Reiterated Rating
9/30/2019	Trilogy International Partners	Royal Bank of Canada	Upgrade
9/25/2019	Allergy Therapeutics	FinnCap	Reiterated Rating
9/10/2019	Futura Medical	Liberum Capital	Reiterated Rating
7/11/2019	Allergy Therapeutics	FinnCap	Reiterated Rating
6/28/2019	Allergy Therapeutics	FinnCap	Reiterated Rating
6/17/2019	Futura Medical	Liberum Capital	Initiated Coverage
4/29/2019	Allergy Therapeutics	FinnCap	Reiterated Rating
4/1/2019	Trilogy International Partners	Royal Bank of Canada	Boost Price Target
3/22/2019	Allergy Therapeutics	FinnCap	Lower Price Target
3/18/2019	Allergy Therapeutics	Numis Securities	Reiterated Rating
3/6/2019	Allergy Therapeutics	Numis Securities	Reiterated Rating
3/6/2019	Allergy Therapeutics	FinnCap	Reiterated Rating
2/20/2019	Trilogy International Partners	TD Securities	Boost Price Target
1/16/2019	Allergy Therapeutics	FinnCap	Reiterated Rating
11/21/2018	Trilogy International Partners	TD Securities	Upgrade
11/13/2018	Trilogy International Partners	Royal Bank of Canada	Downgrade
11/9/2018	Trilogy International Partners	TD Securities	Lower Price Target
10/16/2018	Trilogy International Partners	TD Securities	Lower Price Target
9/27/2018	Allergy Therapeutics	FinnCap	Reiterated Rating
9/26/2018	Allergy Therapeutics	Numis Securities	Reiterated Rating

(Data available from 7/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources